---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-26-000662"
form_type: "8-K"
ticker: "ARTL"
cik: "0001621221"
company_name: "ARTELO BIOSCIENCES, INC."
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T07:01:51.316933+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Artelo Biosciences regains Nasdaq compliance; monitored for one year

## Summary
- Nasdaq confirmed compliance with Equity Rule (≥$2.5M stockholders' equity) and Annual Meeting Rule.
- Subject to mandatory panel monitor through April 6, 2027; re-deficiency could trigger delisting.
- CEO cites focus on ART27.13 (cancer cachexia) Phase 2 data, ART26.12 (neuropathic pain), and partnerships.
- Common stock trades on Nasdaq under ticker ARTL.

## SEC filing metadata
- accession: 0001640334-26-000662
- form_type: 8-K
- ticker: ARTL
- cik: 0001621221
- company_name: ARTELO BIOSCIENCES, INC.
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621221/000164033426000662/0001640334-26-000662-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621221/000164033426000662/artl_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-26-000662
- JSON: https://secwatch.observer/filing/0001640334-26-000662.json
- Plain text: https://secwatch.observer/filing/0001640334-26-000662.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.